ARCA biopharma to Present at the Growth Capital Expo 2014

  ARCA biopharma to Present at the Growth Capital Expo 2014

Growth Capital Expo 2014

Business Wire

WESTMINSTER, Colo. -- April 22, 2014

ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company developing
genetically-targeted therapies for cardiovascular diseases, today announced
that its Chief Financial Officer, Patrick Wheeler, will present at the Growth
Capital Expo 2014, taking place April 29 – May 1, 2014. ARCA’s presentation
will take place Wednesday, April 30, 2014 at 10:30am PT. The Company’s
presentation will be posted in the Investor Relations section of its website
(www.arcabiopharma.com) and will also be available via webcast at:
http://wsw.com/webcast/gce/abio/.

About ARCA biopharma

ARCA biopharma is dedicated to developing genetically-targeted therapies for
cardiovascular diseases. The Company's lead product candidate, Gencaro^TM
(bucindolol hydrochloride), is an investigational, pharmacologically unique
beta-blocker and mild vasodilator being developed for atrial fibrillation.
ARCA has identified common genetic variations that it believes predict
individual patient response to Gencaro, giving it the potential to be the
first genetically-targeted atrial fibrillation prevention treatment. ARCA has
a collaboration with Medtronic, Inc. for support of the GENETIC-AF trial. For
more information please visit www.arcabiopharma.com.

Safe Harbor Statement

This press release and the anticipated presentation contain "forward-looking
statements" for purposes of the safe harbor provided by the Private Securities
Litigation Reform Act of 1995. These statements include, but are not limited
to, statements regarding potential timing for patient enrollment in the
GENETIC-AF trial, the sufficiency of the Company’s capital to support its
operations, the potential for genetic variations to predict individual patient
response to Gencaro, Gencaro’s potential to treat atrial fibrillation, the
role of AF burden in diagnosis and treatment of atrial fibrillation and the
potential for Gencaro to be the first genetically-targeted atrial fibrillation
prevention treatment. Such statements are based on management's current
expectations and involve risks and uncertainties. Actual results and
performance could differ materially from those projected in the
forward-looking statements as a result of many factors, including, without
limitation, the risks and uncertainties associated with: the Company's
financial resources and whether they will be sufficient to meet the Company's
business objectives and operational requirements; results of earlier clinical
trials may not be confirmed in future trials, the protection and market
exclusivity provided by the Company’s intellectual property; risks related to
the drug discovery and the regulatory approval process; and the impact of
competitive products and technological changes. These and other factors are
identified and described in more detail in ARCA’s filings with the SEC,
including without limitation the Company’s annual report on Form 10-K for the
year ended December 31, 2013, and subsequent filings. The Company disclaims
any intent or obligation to update these forward-looking statements.

Contact:

ARCA biopharma, Inc.
Derek Cole, 720-940-2163
derek.cole@arcabiopharma.com
 
Press spacebar to pause and continue. Press esc to stop.